S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
Log in

NASDAQ:THTX - Theratechnologies Stock Price, Forecast & News

$1.57
+0.04 (+2.61 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$1.43
Now: $1.57
$1.73
50-Day Range
$1.43
MA: $2.40
$3.21
52-Week Range
$1.33
Now: $1.57
$6.68
Volume115,086 shs
Average Volume146,489 shs
Market Capitalization$120.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:THTX
CUSIPN/A
CIKN/A
Phone514-336-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.22 million
Book Value$0.32 per share

Profitability

Net Income$-12,500,000.00

Miscellaneous

Employees32
Market Cap$120.81 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive THTX News and Ratings via Email

Sign-up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.


Theratechnologies (NASDAQ:THTX) Frequently Asked Questions

How has Theratechnologies' stock been impacted by COVID-19 (Coronavirus)?

Theratechnologies' stock was trading at $2.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, THTX stock has decreased by 28.3% and is now trading at $1.57. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Theratechnologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Theratechnologies.

When is Theratechnologies' next earnings date?

Theratechnologies is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Theratechnologies.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) issued its earnings results on Tuesday, February, 25th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02. The company had revenue of $16.40 million for the quarter, compared to the consensus estimate of $16.48 million. Theratechnologies had a negative return on equity of 37.48% and a negative net margin of 19.77%. View Theratechnologies' earnings history.

What price target have analysts set for THTX?

2 brokers have issued 1 year price targets for Theratechnologies' stock. Their forecasts range from $5.80 to $95.50. On average, they expect Theratechnologies' share price to reach $50.65 in the next twelve months. This suggests a possible upside of 3,126.1% from the stock's current price. View analysts' price targets for Theratechnologies.

Has Theratechnologies been receiving favorable news coverage?

News coverage about THTX stock has trended very positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theratechnologies earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutTheratechnologies.

Are investors shorting Theratechnologies?

Theratechnologies saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 1,074,600 shares, a drop of 22.7% from the February 27th total of 1,390,000 shares. Based on an average daily volume of 140,900 shares, the days-to-cover ratio is presently 7.6 days. Currently, 1.4% of the shares of the stock are short sold. View Theratechnologies' Current Options Chain.

Who are some of Theratechnologies' key competitors?

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Alibaba Group (BABA), Theratechnologies (TH), EXACT Sciences (EXAS), Aimmune Therapeutics (AIMT), Dropbox (DBX), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), LYFT (LYFT), Roku (ROKU) and Tesla (TSLA).

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the following people:
  • Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 61)
  • Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 52)
  • Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 51)
  • Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 53)
  • Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 56)

What is Theratechnologies' stock symbol?

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Caisse DE Depot ET Placement DU Quebec (2.60%), Boston Private Wealth LLC (1.08%), Stifel Financial Corp (0.31%), Swiss National Bank (0.19%), Renaissance Technologies LLC (0.14%) and Advisor Group Inc. (0.13%).

Which major investors are selling Theratechnologies stock?

THTX stock was sold by a variety of institutional investors in the last quarter, including Boston Private Wealth LLC.

Which major investors are buying Theratechnologies stock?

THTX stock was bought by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Stifel Financial Corp, Swiss National Bank, Renaissance Technologies LLC, Advisor Group Inc., PNC Financial Services Group Inc., Belpointe Asset Management LLC, and Bank of Montreal Can.

How do I buy shares of Theratechnologies?

Shares of THTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Theratechnologies' stock price today?

One share of THTX stock can currently be purchased for approximately $1.57.

How big of a company is Theratechnologies?

Theratechnologies has a market capitalization of $120.81 million and generates $63.22 million in revenue each year. The company earns $-12,500,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Theratechnologies employs 32 workers across the globe. View additional information about Theratechnologies.

What is Theratechnologies' official website?

The official website for Theratechnologies is http://www.theratech.com/.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company can be reached via phone at 514-336-7800 or via email at [email protected]


MarketBeat Community Rating for Theratechnologies (NASDAQ THTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe THTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel